Skip to main content
SPARC - Logo
Innovations Inspired by life
Menu

Hamburger

  • Our Company
    • Who we are
    • History
    • Culture
    • Board of Directors
    • Leadership Team
  • OUR RESEARCH
    • Therapeutic focus
    • Delivery Technologies
    • Research Programs
    • R&D Pipeline
  • Our Medicines
    • Xelpros®
    • Elepsia® XR
  • Business Development
    • Strategy
    • Partner with us
  • Accreditations And Approvals
    • Good Laboratory Practice
  • Investors
    • Who we are
    • Financials
    • Annual reports
    • Presentations
    • Chairman's Speech
    • Committees of BOD's
    • Shareholding pattern
    • Announcements & Disclosures
    • Policies & Codes
    • Listing Information
    • Board of Directors
    • FAQ’s, Guide Book and Forms for Shareholders
    • Investors Contact
    • Go green
    • IEPF
  • Media
    • Press Releases
    • Presentations
  • Careers
    • Overview
    • Apply Now
  • Contact Us
Home » Our Medicines
  • Our Medicines
    • Xelpros ®
    • Elepsia® XR

Xelpros®

Xelpros® is a novel, translucent, almost colorless, BAK-free Latanoprost Ophthalmic Emulsion developed with LipixelleTM Technology.

Prostaglandin analogues such as Latanoprost are the first line treatment for open-angle glaucoma or ocular hypertension and form the largest drug class.

The currently marketed Latanoprost Eye Drops contain Benzalkonium Chloride (BAK). BAK is a common preservative in topical ocular preparations; however, prolonged use may lead to deleterious effects on the ocular surface, affecting quality of life and reducing adherence to treatment and overall outcomes. Use of BAK has been associated with the increased risk of developing OSD1. Patients with OSD, experience symptoms of ocular discomfort like dryness, burning or stinging, itching, irritation, tearing, etc. These symptoms can have a substantial impact on a patient’s quality of life and potentially lead to reduced adherence with treatment regimens.

In a head to head comparative study in Glaucoma patients, Xelpros® was found to be as efficacious and as safe as Xalatan.

Xelpros® offers a novel and BAK free treatment option for patients with open-angle glaucoma or ocular hypertension. Xelpros®, unlike other marketed products of Latanoprost, is stable at room temperature and does not require storage at 2-80C.

Xelpros® is now approved by USFDA and is licensed and commercialized in the US market by a subsidiary of Sun Pharmaceutical Industries Limited.

1. J Glaucoma. 2008 Aug;17(5):350-5

Our Company

  • Who we are
  • history
  • Culture
  • board of directors
  • Leadership team

Our Research

  • Therapeutic focus
  • Delivery Technologies
  • Research Programs
  • R&D Pipeline

Investor Relations

  • Financials
  • Announcements & Disclosures
  • Shareholding pattern
  • Listing Information

Quick Links

Quick Links

  • Business Development
  • Investors
  • Media
  • Careers

Social Connect

  • twitter
  • linkedin

Employee Portal »

Copyright © 2019. Sun Pharma Advanced Research Company Ltd. All rights reserved.
Terms of Use  |   Archival Policy   |   Sitemap
Site Credits